Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?

被引：11

作者：

Athyros, Vasilios G. ^{[2
]}

Kakafika, Anna I. ^{[2
]}

Tziomalos, Konstantinos ^{[1
]}

Karagiannis, Asterios ^{[2
]}

Mikhailidis, Dimitri P. ^{[1
]}

机构：

[1] Univ London, Royal Free Hosp, Univ Coll London,Vasc Prevent Clin, Royal Free & Univ Coll Med Sch,Dept Clin Biochem, London NW3 2QG, England

[2] Aristotle Univ Thessaloniki, Propedeut Dept Internal Med 2, Hippokration Hosp, Sch Med, GR-54006 Thessaloniki, Greece

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2008年 / 17卷 / 07期

关键词：

antisense oligonucleotide; cardiovascular disease; gene expression; low-density lipoprotein cholesterol; mipomersen; RNA;

D O I：

10.1517/13543784.17.7.969

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Antisense technology might be a gateway to the treatment of diseases by targeting the expression of genes rather than permanently altering them. Thus, there will be fewer ethical concerns. Antisense oligonucleoticles (ASO) can alter target gene expression by binding to RNA. Once bound, the ASO either disables or induces the degradation of the target RNA. This technology may be used to treat various conditions (including cancer, diabetes, and hypertension, as well as autoimmune and cardiovascular diseases). ASOs are potentially potent, selective and well-tolerated drugs. Mipomersen. (ISIS 301012) inhibits human apolipoprotein (apo)B-100 synthesis and lowers circulating apoB and low-density lipoprotein cholesterol levels. ASO technology, may provide a spectrum of agents targeting other vascular risk factors or mediators of atherosclerosis.

引用

页码：969 / 972

页数：4

共 29 条

[1] Antisense apolipoprotein B therapy: where do we stand? [J].

Akdim, Fatima ;

Stroes, Erik S. G. ;

Kastelein, John J. P. .

CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (04) :397-400

[2] Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study [J].

Athyros, Vasilios G. ;

Mikhailidis, Dimitri P. ;

Didangelos, Triandafillos P. ;

Giouleme, Olga I. ;

Liberopoulos, Evangelos N. ;

Karagiannis, Asterios ;

Kakafika, Anna I. ;

Tziomalos, Konstantinos ;

Burroughs, Andrew K. ;

Elisaf, Moses S. .

CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) :873-883

[3] Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia [J].

Athyros, VG ;

Papageorgiou, AA ;

Athyrou, VV ;

Demitriadis, DS ;

Pehlivanidis, AN ;

Kontopoulos, AG .

JOURNAL OF CARDIOVASCULAR RISK, 2002, 9 (01) :33-39

[4] Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia [J].

Athyros, VG ;

Papageorgiou, AA ;

Athyrou, VV ;

Demitriadis, DS ;

Kontopoulos, AG .

DIABETES CARE, 2002, 25 (07) :1198-1202

[5] Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia [J].

Athyros, VG ;

Papageorgiou, AA ;

Hatzikonstandinou, HA ;

Didangelos, TP ;

Carina, MV ;

Kranitsas, DF ;

Kontopoulos, AG .

AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (05) :608-613

[6] Statin-fibrate combinations in patients with combined hyperlipidemia [J].

Athyros, VG ;

Papageorgiou, AA ;

Kontopoulos, AC .

ATHEROSCLEROSIS, 2001, 155 (01) :263-264

[7]

ATHYROS VG, 2008, ATHEROSCLEROSIS

[8] Liver-specific inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice [J].

Bell, Thomas A., III ;

Brown, J. Mark ;

Graham, Mark J. ;

Lemonidis, Kristina A. ;

Crooke, Rosanne M. ;

Rudel, Lawrence L. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (08) :1814-1820

[9]

Burnett JR, 2006, CURR OPIN MOL THER, V8, P461

[10] Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance [J].

Choi, Cheol Soo ;

Savage, David B. ;

Kulkarni, Ameya ;

Yu, Xing Xian ;

Liu, Zhen-Xiang ;

Morino, Katsutaro ;

Kim, Sheene ;

Distefano, Alberto ;

Samuel, Varman T. ;

Neschen, Susanne ;

Zhang, Dongyan ;

Wang, Amy ;

Zhang, Xian-Man ;

Kahn, Mario ;

Cline, Gary W. ;

Pandey, Sanjay K. ;

Geisler, John G. ;

Bhanot, Sanjay ;

Monia, Brett P. ;

Shulman, Gerald I. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (31) :22678-22688

← 1 2 3 →